Table 2.
Characteristics of patients
| Characteristic | No. (%) |
|---|---|
| Age, median (range, mo) | 2.0 (0.0-16.7) |
| Sex | |
| Male | 36 (50.0) |
| Female | 36 (50.0) |
| Primary site | |
| Abdomen | 55 (76.4) |
| Posterior mediastinum | 15 (20.8) |
| Neck | 2 (2.8) |
| INSS stage | |
| Stage I | 16 (22.2) |
| Stage II | 8 (11.1) |
| Stage III | 16 (22.2) |
| Stage IV | 31 (43.1) |
| Stage IVs | 1 (1.4) |
| Risk group | |
| Low risk | 24 (33.3) |
| Intermediate risk | 21 (29.2) |
| High risk | 27 (37.5) |
| MYCN amplification | |
| Positive | 7/70 (10.0) |
| Negative | 63/70 (90.0) |
| ALK IHC | |
| Positive | 40 (55.6) |
| Negative | 32 (44.4) |
| ATRX IHC | |
| Loss | 9/69 (13.0) |
| No loss | 60/69 (87.0) |
| TERT IHC | |
| Positive | 42/71 (59.2) |
| Negative | 29/71 (40.8) |
INSS, International Neuroblastoma Staging System; ALK, anaplastic lymphoma kinase; IHC, immunohistochemistry; ATRX, alpha thalassemia/mental retardation syndrome X-linked; TERT, telomerase reverse transcriptase.